RECURRENT CANCER

This study tests a personalized vaccine made from each patient's unique tumor mutations. The vaccine is designed to train the immune system to attack the cancer. Ten adults with advanced or high-risk solid tumors will receive the vaccine along with immune-boosting drugs. The goal…

This trial tests whether giving children and teens with advanced solid tumors, brain tumors, or lymphomas drugs that target their specific tumor's genetic changes can help. About 90 participants will receive one of four drug combinations based on their tumor profile. The goal is …

This study tests a new approach for people with solid tumors that have come back or not responded to standard treatments. Researchers take a patient's own immune cells, genetically modify them to recognize a protein called PRAME found on many cancer cells, and infuse them back. S…

This study tests a combination of three drugs—pembrolizumab, ibrutinib, and rituximab—in people whose primary central nervous system lymphoma has come back or not responded to prior treatment. The goal is to see if the combo can stop the cancer from growing for at least 6 months.…

This study tests a drug called cabozantinib in 20 adults whose liver cancer returned after a liver transplant. The goal is to see if the drug can control the cancer. Participants take the drug until it stops working or side effects become too bothersome.

This study is testing a new way to deliver radiation for cervical cancer or pelvic cancer that has come back. It is for patients whose cancer cannot be treated with the usual brachytherapy method because of unusual anatomy or large tumors. The goal is to see if this new technique…

This early-stage trial tests a new drug, IMA402, designed to help the immune system attack cancer cells. It is for adults with solid tumors that have returned or not responded to standard treatments. The study aims to find a safe dose and check if the drug can shrink tumors.